MX2009004061A - Compuestos organicos. - Google Patents

Compuestos organicos.

Info

Publication number
MX2009004061A
MX2009004061A MX2009004061A MX2009004061A MX2009004061A MX 2009004061 A MX2009004061 A MX 2009004061A MX 2009004061 A MX2009004061 A MX 2009004061A MX 2009004061 A MX2009004061 A MX 2009004061A MX 2009004061 A MX2009004061 A MX 2009004061A
Authority
MX
Mexico
Prior art keywords
organic compounds
iap
predict
administering
respond
Prior art date
Application number
MX2009004061A
Other languages
English (en)
Spanish (es)
Inventor
Vadim Iourgenko
Mark Aron Labow
Leigh Zawel
Larry Alexander Gaither
Christopher Sean Straub
Dale Alan Porter
Yao Yao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009004061A publication Critical patent/MX2009004061A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
MX2009004061A 2006-10-19 2007-10-17 Compuestos organicos. MX2009004061A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86215506P 2006-10-19 2006-10-19
US86216106P 2006-10-19 2006-10-19
PCT/US2007/022125 WO2008057172A2 (en) 2006-10-19 2007-10-17 Organic compounds

Publications (1)

Publication Number Publication Date
MX2009004061A true MX2009004061A (es) 2009-04-27

Family

ID=39364966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004061A MX2009004061A (es) 2006-10-19 2007-10-17 Compuestos organicos.

Country Status (10)

Country Link
US (1) US20100316573A1 (cg-RX-API-DMAC10.html)
EP (1) EP2076778A2 (cg-RX-API-DMAC10.html)
JP (1) JP2010507096A (cg-RX-API-DMAC10.html)
KR (1) KR20090082221A (cg-RX-API-DMAC10.html)
AU (1) AU2007318220A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0717411A2 (cg-RX-API-DMAC10.html)
CA (1) CA2665838A1 (cg-RX-API-DMAC10.html)
MX (1) MX2009004061A (cg-RX-API-DMAC10.html)
RU (1) RU2009118487A (cg-RX-API-DMAC10.html)
WO (1) WO2008057172A2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
EA012810B1 (ru) 2005-02-25 2009-12-30 Тетралоджик Фармасеутикалс Димерные ингибиторы ингибиторов белков апоптоза (iap)
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
US20090005411A1 (en) * 2005-12-20 2009-01-01 Novartic Ag Combinations of Organic Compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
MX2009000824A (es) 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
EP2296650B1 (en) * 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
JP2013505446A (ja) * 2009-09-18 2013-02-14 ノバルティス アーゲー Ｉａｐ阻害剤化合物のためのバイオマーカー
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
KR20150011822A (ko) 2012-05-04 2015-02-02 노파르티스 아게 Iap 억제제 요법을 위한 바이오마커
GB201305376D0 (en) * 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR102166292B1 (ko) * 2018-11-13 2020-10-15 국민대학교 산학협력단 퀴논계 화합물을 유효성분으로 포함하는 피부 미백용 조성물 및 그 화합물의 스크리닝 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1933847A (zh) * 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
US20100316573A1 (en) 2010-12-16
JP2010507096A (ja) 2010-03-04
KR20090082221A (ko) 2009-07-29
AU2007318220A1 (en) 2008-05-15
EP2076778A2 (en) 2009-07-08
WO2008057172A2 (en) 2008-05-15
BRPI0717411A2 (pt) 2013-11-12
RU2009118487A (ru) 2010-11-27
WO2008057172A3 (en) 2008-09-12
CA2665838A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008057172A3 (en) Organic compounds
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
MX2010009736A (es) Compuesto heterociclico.
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
IN2014CN02483A (cg-RX-API-DMAC10.html)
PT2359834T (pt) Tratamento de doentes com hemoglobimúria paroxística noturna por meio de um inibidor de complemento
EA200870357A1 (ru) Производные тетрагидроизохинолина для повышения функции памяти
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
EA200801945A1 (ru) Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
MX2011008289A (es) Tabletas para terapia combinada.
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
NO346368B1 (no) En fremgangsmåte for konsentrasjon av alfa-mannosidase.
UA107583C2 (ru) Спироциклические нитрилы как ингибиторы протеазы
MX2010005114A (es) Uso de las soluciones de aceite de menta o de l-carvona para el tratamiento fungicida y/o antigerminacion de bulbos y/o tuberculos.
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
CL2011002569A1 (es) Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.
WO2009101199A3 (en) Treatment of acne vulgaris; rosacea and rhinophym
MX2009005249A (es) Compuestos organicos.
TW200700071A (en) Novel use
WO2007115287A3 (en) Combination of organic compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal